Microbot Medical

MBOT

Market cap $150M

Overview Fund Activity

3.10 USD

-0.22

6.63%

At close Updated Sep 18, 2:11 PM EDT

1 day

-6.63%

5 days

-22.5%

1 month

0.65%

3 months

25.51%

6 months

81.29%

Year to date

171.93%

1 year

234.99%

5 years

-59.53%

10 years

-99.62%

About: Microbot Medical Inc is a breakthrough medical device company. The group is focused on transforming endovascular procedures through advanced robotic technology. Microbot's LIBERTY Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and provider safety. With a robust intellectual property portfolio and a deep commitment to innovation, Microbot is shaping the future of endovascular care.

Employees: 22

Healthcare Medical Instruments & Supplies

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

2,464% more call options, than puts

Call options by funds: $4.64M | Put options by funds: $181K

239% more capital invested

Capital invested by funds: $3.26M [Q1] → $11M (+$7.79M) [Q2]

75% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 8

30% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 10

14% more funds holding

Funds holding: 43 [Q1] → 49 (+6) [Q2]

5.84% more ownership

Funds ownership: 6.21% [Q1] → 12.05% (+5.84%) [Q2]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$12

287% upside

Avg. target

$12

287% upside

High target

$12

287% upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co.

Raghuram Selvaraju

$12

Buy

Maintained

11 Sep 2025

See Analyst Rankings

Financial journalist opinion

Based on 8 articles about MBOT published over the past 30 days

Microbot Medical Announces First Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds

$25.2 million in first closing and $4 million in second closing, with up to an additional approximately $63 million of potential aggregate gross proceeds upon the exercise in full of short-term preferred investment options $25.2 million in first closing and $4 million in second closing, with up to an additional approximately $63 million of potential aggregate gross proceeds upon the exercise in full of short-term preferred investment options

Microbot Medical Announces First Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds

Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for Up to $92.2 Million in Gross Proceeds

BRAINTREE, Mass., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) (“Microbot” or the “Company”), today announced the entry into definitive agreements for the exercise of certain outstanding preferred investment options to purchase up to an aggregate of 13,989,115 shares of common stock.

Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for Up to $92.2 Million in Gross Proceeds

Zacks Investment Research

Microbot Shares Rise on FDA Clearance for LIBERTY Robotic System

MBOT shares rise as FDA clears its LIBERTY robotic system, paving the way for U.S. market entry and fueling strong investor momentum.

Microbot Shares Rise on FDA Clearance for LIBERTY Robotic System

REMINDER: Microbot Medical to Highlight FDA 510(k) Clearance of the LIBERTY Endovascular Robotic System at the H.C. Wainwright Annual Investor Conference

HINGHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and manufacturer of the innovative LIBERTY® Endovascular Robotic System, today announced that Harel Gadot, CEO, President & Chairman, will highlight the recent FDA clearance of the LIBERTY® System, the first single-use, remotely operated robotic system for peripheral endovascular procedures, at the H.C.

REMINDER: Microbot Medical to Highlight FDA 510(k) Clearance of the LIBERTY Endovascular Robotic System at the H.C. Wainwright Annual Investor Conference

Microbot Medical® Receives FDA 510(k) Clearance for Its LIBERTY® Endovascular Robotic System

Accelerated Launch Readiness Plans Position Company for Commercialization during Q4 2025 The Company's Initial Addressable Market Includes Approximately 2.5 Million Peripheral Endovascular Procedures in the U.S. Annually CEO, President & Chairman to Present Live Webcast at the H.C. Wainwright Annual Investor Conference on September 9, 2025, at 9 AM ET.

Microbot Medical® Receives FDA 510(k) Clearance for Its LIBERTY® Endovascular Robotic System

Microbot Medical: LIBERTY's Disposable Endovascular Robot Nears FDA Catalyst

MBOT's main value driver is its LIBERTY robot. This is a disposable, portable endovascular robot that has great potential. LIBERTY showed strong ACCESS-PVI data and now awaits FDA 510(k) clearance for a tentative US launch. If approved, MBOT could generate revenues from selling this robot, plus some miscellaneous per-procedure consumables.

Microbot Medical: LIBERTY's Disposable Endovascular Robot Nears FDA Catalyst

Zacks Investment Research

Microbot Shares Rise as New U.S. Patent Expands LIBERTY System Market

MBOT's new U.S. patent boosts the LIBERTY system's flexibility, expanding its U.S. market reach to over six million annual procedures.

Microbot Shares Rise as New U.S. Patent Expands LIBERTY System Market

Microbot Medical® Granted U.S. Patent that Significantly Expands Potential Market Applications

With the Newly Granted IP, the Company's IP Portfolio for the LIBERTY ® System now includes 12 patents granted globally and 57 patent applications pending.

Microbot Medical® Granted U.S. Patent that Significantly Expands Potential Market Applications

Microbot Medical® Receives Non-Dilutive Grant to Enhance Operational Capabilities

HINGHAM, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced it has been approved to receive a non-dilutive grant from the Israel Innovation Authority ("IIA”) in the amount of NIS 2.15 Million (approximately $630,000 at a recent exchange rate).

Microbot Medical® Receives Non-Dilutive Grant to Enhance Operational Capabilities

Microbot Medical® Expands Commercial Leadership with Appointment of Christina Bailey as VP of Sales

HINGHAM, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced the appointment of Christina Bailey as its new Vice President of Sales.

Microbot Medical® Expands Commercial Leadership with Appointment of Christina Bailey as VP of Sales

See News Rankings

Charts implemented using Lightweight Charts™